MoonLake Immunotherapeutics Stock Forecast
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:00 PM ET
MLTX analyst consensus
Consensus (15 analysts)
buy
Avg. price target
$28.54+182.57%
- Strong buy 1
- Buy 10
- Hold 2
- Sell 2
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 15 Wall Street analysts covering MoonLake Immunotherapeutics (2026-10-08), 11 rate the stock a buy or strong buy, 2 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $28.54, with a high estimate of $50.00 and a low estimate of $6.00. The average target implies upside of 182.6% from the current price of $10.10.
The spread between the highest and lowest targets is 733.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MLTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 7% |
| Buy | 10 | 67% |
| Hold | 2 | 13% |
| Sell | 2 | 13% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $6.00 | -40.59% |
| Average target | $28.54 | +182.57% |
| High target | $50.00 | +395.05% |